SPDR Advertisement SureTrader SureTrader SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

MNKD RSS Feed
Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TREND1, conix, MadHatter326, frosr6, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 7/5/2015 3:21:48 PM - Followers: 311 - Board type: Free - Posts Today: 21



Welcome to MannKind Board!!!


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at: http://www.mannkindcorp.com/about-us-overview.htm#sthash.6MYBImtD.dpuf


 
MANNKIND CORP

Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio

 

Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge


http://www.mannkindcorp.com/

http://www.mnkd.proboards.com/  A good forum for discussion on Mankind

http://finance.yahoo.com/q/ks?s=MNKD

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.



Nasdaq.com;
http://www.nasdaq.com/symbol/mnkd/institutional-holdings
Sec.gov;
http://www.sec.gov/cgi-bin/browse-edgar?CIK=Mnkd&Find=Search&owner=exclude&action=getcompany
 







 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MNKD
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for MNKD
MNKD News: 3 Biotech Stocks with Low Liquidity Ratios -- Are They in Trouble? 06/29/2015 09:03:02 AM
MNKD News: What Is a Short Squeeze, and How Can it Affect Your Investments? 06/19/2015 05:08:02 PM
MNKD News: 3 Biotech Stocks That I Won't Buy 06/13/2015 08:04:03 AM
MNKD News: Why MannKind Corp. Stock Bolted Higher Today 06/08/2015 12:06:20 PM
MNKD News: MannKind Corporation Shares Skyrocketed in May -- Here's Why 06/03/2015 08:01:02 AM
PostSubject
#12838  Sticky Note What would be positive for MNKD ? TREND1 07/05/15 12:40:53 PM
#12816  Sticky Note $MNKD 3 Reasons MannKind Corporation's Stock Could Fall[ $Pistol Pete$ 07/04/15 08:02:19 PM
#12561  Sticky Note Its in the financial disclosure/announcement - see my Jack4656 06/24/15 05:17:36 PM
#12078  Sticky Note SHORT INTEREST--As of 5/29/15--131 Million Shares Short conix 06/10/15 10:14:43 AM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#12848   f6 Are you going to up date the intro ? TREND1 07/05/15 03:21:48 PM
#12847   So the question is I'm sure for any frosr6 07/05/15 03:18:12 PM
#12845   JLS I am not sure SNY has rights to TREND1 07/05/15 03:03:41 PM
#12844   Sanofi thinking out loud: JLS 07/05/15 02:57:09 PM
#12842   To get to the CORRECT finish, you must TREND1 07/05/15 02:39:27 PM
#12841   It's not where you start, it's where you finish. yosemite47 07/05/15 02:29:40 PM
#12838   What would be positive for MNKD ? TREND1 07/05/15 12:40:53 PM
#12837   Well stated. Mahalo. eom Denise Chanterelle 07/05/15 11:36:11 AM
#12835   SNY isn't manufacturing the drug. Mannkind is. Hardly SidVicious 07/05/15 10:31:08 AM
#12834   Despite all the warnings, warnings that have been SidVicious 07/05/15 10:18:26 AM
#12832   I know everyone wants to compare the two SidVicious 07/05/15 10:02:39 AM
#12831   So why is SNY still backing Afrezza (as SidVicious 07/05/15 09:58:26 AM
#12829   $MNKD Sanofi/MannKind might be facing a major flop $Pistol Pete$ 07/05/15 03:16:44 AM
#12828   The greatest confirmation of Afrezza effectiveness on a tyfoidhana 07/05/15 12:28:28 AM
#12827   Two good Seeking Alpha articles out this weekend Hypi 07/04/15 11:44:22 PM
#12825   morning star The warnings have been there. TREND1 07/04/15 09:35:55 PM
#12824   SNY pays 100% of the bills TREND1 07/04/15 09:24:58 PM
#12822   EXUBREA produced 12 million in sales in 28 weeks TREND1 07/04/15 09:16:21 PM
#12821   HOW CAN AFREZZA BE A BLOCK BUSTER with TREND1 07/04/15 09:11:49 PM
#12816   $MNKD 3 Reasons MannKind Corporation's Stock Could Fall[ $Pistol Pete$ 07/04/15 08:02:19 PM
#12814   $MNKD Afrezza’s Underperformance Is a Cause of Concern $Pistol Pete$ 07/04/15 07:09:53 PM
#12813   $MNKD It was declared in May that company $Pistol Pete$ 07/04/15 07:07:44 PM
#12812   To me, they own MNKD 100%. They are $Pistol Pete$ 07/04/15 07:02:12 PM
#12811   Since SNY pays 100% of the bills, it TREND1 07/04/15 06:53:11 PM
#12810   I agreed that MNKD is just a shell $Pistol Pete$ 07/04/15 06:42:15 PM
#12809   $MNKD MannKind: ‘Early Launch Struggles Could Be Di $Pistol Pete$ 07/04/15 06:32:38 PM
#12808   $MNKD MannKind Corporation Sinks: CFO Says 'We $Pistol Pete$ 07/04/15 06:29:57 PM
#12807   $MNKD MannKind's Afrezza Lags Behind Biggest Failu $Pistol Pete$ 07/04/15 06:27:10 PM
#12806   Not exactly correct. While some may be able SidVicious 07/04/15 03:18:57 PM
#12805   4 out of 5 fake diabetics hate Afreeza Anguspunch 07/04/15 12:19:07 PM
#12804   One GIANT leap for mankind. DaddyPennyLegs 07/04/15 02:00:30 AM
#12800   MNKD is just a shell company. TREND1 07/03/15 10:19:14 PM
#12798   Phaeton, JLS 07/03/15 09:29:45 PM
#12797   No dream Jack. Sales are UP. I'm here Denise Chanterelle 07/03/15 08:46:06 PM
#12796   "The idea is not new, the execution and JLS 07/03/15 08:08:52 PM
#12795   JACK You are a dreamer .... TREND1 07/03/15 05:36:43 PM
#12794   do they even need ads? Jack4656 07/03/15 05:26:38 PM
#12793   What happens after the adds fail ? TREND1 07/03/15 05:05:12 PM
#12790   Exactly - Afrezza will take diabetics off injection, Jack4656 07/03/15 03:24:50 PM
#12789   Phaeton Another week and another 2.7 million loss for AFREZZA. TREND1 07/03/15 02:58:03 PM
#12788   No profit today as it's a newly released Phaeton 07/03/15 02:16:10 PM
#12787   No, I'm not comparing cars. JLS 07/03/15 02:08:49 PM
#12786   Those numbers are estimates, with large error bars Jack4656 07/03/15 01:22:04 PM
#12785   BOOM! Google trends shows search for 'spirometry' is at Jack4656 07/03/15 01:14:58 PM
#12784   JACK You and I agree that AFREZZA is a TREND1 07/03/15 01:08:42 PM
#12783   Yep...MNKD need buying pressure, without it. It hard $Pistol Pete$ 07/03/15 12:51:25 PM
#12782   90% was hit. I will watch how MNKD $Pistol Pete$ 07/03/15 12:48:17 PM
#12781   You are comparing GM's EV1 to Tesla's Model S. Jack4656 07/03/15 12:42:52 PM
#12780   Good gains. Hopefully we will see in a SidVicious 07/03/15 09:55:46 AM
#12779   Symphony TRX 516 (+22%) NRX 386 (+17%) refills Cave In Temptor 07/03/15 09:36:04 AM
PostSubject